This risk minimisation material provides recommendations for the use of Pradaxa for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from the time the child is able to swallow food to less than 18 years of age (paed. VTE) in order to minimise the risk of bleeding. Please ensure you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa in the paediatric population and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]